The NCI-designated Sidney Kimmel Cancer Center (SKCC) is the heart of Jefferson’s broad-based cancer research program. SKCC investigators are currently pursuing hundreds of basic science, translational and clinical studies on cancer cell biology and signaling, molecular biology and genetics, and specific diseases ranging from brain cancer to uveal melanoma. Among the most exciting efforts are partnerships between SKCC basic scientists and clinician-researchers to both advance new immune-based therapies and continuously improve current approaches.
"Advancing Cellular and Immune-Based Cancer Therapies,"
Thomas Jefferson University Research Magazine: Vol. 1:
1, Article 3.
Available at: https://jdc.jefferson.edu/researchmagazine/vol1/iss1/3